Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management.

导出原文传递

翻译打印收藏纠错

第一作者： Chiara,Casadei

第一单位： Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

作者： Chiara,Casadei ^[1] ; Giuseppe,Schepisi ^[1] ; Cecilia,Menna ^[1] ; Michal,Chovanec ^[2] ; Giorgia,Gurioli ^[3] ; Valentina,Gallà ^[4] ; Amelia,Altavilla ^[1] ; Massimo,Marcellini ^[5] ; Salvatore Roberto,Bellia ^[6] ; Cristian,Lolli ^[1] ; Michal,Mego ^[2] ; Giovanni,Rosti ^[7] ; Ugo,De Giorgi ^[1]

作者单位： Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ^[1] Second Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. ^[2] Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ^[3] Unit of Biostatistics & Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ^[4] Medical Oncology, Principe di Piemonte Hospital, Senigallia, Italy. ^[5] Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. ^[6] Department of Oncology, Policlinico San Matteo IRCCS, Pavia, Italy. ^[7]

关键词 biomarkers bleomycin chemotherapy germ cell tumors high-dose human chorionic gonadotropin metastases platinum prognosis seminoma α-fetoprotein